Matthew J. Atherton

Veterinary <scp>Cooperative</scp> Oncology Group—Common Terminology Criteria for Adverse Events (<scp>VCOG‐CTCAE</scp> v2) following investigational therapy in dogs and cats

Amy K. LeBlanc, Matthew J. Atherton, R. Timothy Bentley et al. · Veterinary and Comparative Oncology · 2021 · 322 citations · Full text

Veterinary Medicine, Veterinary Oncology, Veterinary Surgery +15

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

Jonathan Pol, Sergio A. Acuña, Beta Yadollahi et al. · OncoImmunology · 2018 · 87 citations · Full text

Medicine, Immunology, Oncology +17

S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3

Fuan Wang, Tommy Alain, Kristy J. Szretter et al. · Nature Immunology · 2016 · 82 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +11

Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008–2012)

Kathryn Pratschke, Matthew J. Atherton, Jack A Sillito et al. · Journal of the American Veterinary Medical Association · 2013 · 71 citations

Medicine, Oncology, Surgery +17

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma

M. Kazim Panjwani, Matthew J. Atherton, Martha A. MaloneyHuss et al. · OncoImmunology · 2019 · 67 citations · Full text

Medicine, Immunology, Oncology +17